PTC Inc. (PTC) Soars 17.7%: Is Further Upside Left in the Stock?
PTC Inc. (PTC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PTC Stock Pulls Back After Soaring on Report of Possible Autodesk Bid
Shares of software company PTC ended Wednesday's session up 18%.
PTC Unveils Arena SCI for Resilient Product Development
PTC debuts Arena SCI to tackle supply chain risk with AI, even as mounting debt highlights growing financial pressure.
PTC Brings Cloud-Native Model-Based Definition to Onshape
PTC debuts the first cloud-native MBD in Onshape, aiming to cut 2D drawing reliance and streamline product development.
PTC: Margin Strength Meets Valuation Reset
PTC's diversified software suite and high-margin recurring revenue model drive solid fundamentals, despite capability competition from Autodesk and Dassault. Operating margins are expanding, now at ~35%, and PTC trades at a valuation discount versus peers, offering attractive upside if ARR growth reaccelerates. Strategic SaaS pivots and targeted R&D deliver superior margin efficiency and innovation, positioning PTC well for long-term cloud-native trends in industrials.
Why PTC Inc. (PTC) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is PTC Inc. (PTC) Up 7.4% Since Last Earnings Report?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
PTC Inc. (PTC) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PTC Inc. (PTC) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.
PTC's Q2 Earnings & Revenues Top, Improve Y/Y, 2025 Outlook Tweaked
PTC's Q2 performance is driven by solid recurring revenues amid a tough sales backdrop. Fiscal 2025 view is revised based on potential macro volatility.
PTC Inc. (PTC) Q2 2025 Earnings Call Transcript
PTC Inc. (NASDAQ:PTC ) Q3 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Matt Shimao - Head of Investor Relations Neil Barua - President & Chief Executive Officer Kristian Talvitie - Chief Financial Officer Robert Dahdah - Executive Vice President & Chief Revenue Officer Conference Call Participants Daniel Jester - BMO Capital Markets Adam Borg - Stifel Saket Kalia - Barclays Siti Panigrahi - Mizuho Securities Co., Ltd. Ken Wong - Oppenheimer & Co. Inc. Jason Celino - KeyBanc Capital Markets Inc. Jay Vleeschhouwer - Griffin Securities, Inc. Nay Soe Naing - Berenberg Joshua Tilton - Wolfe Research Operator Good afternoon, ladies and gentlemen.
